Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19
NCT04457609Phase 1Unknown
- Sponsor
- Universitas Indonesia
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Universitas Indonesia. Primary endpoints: Presence of dyspnea at 15 days, Presence of sputum at 15 days and 6 more. Status: unknown.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04457609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04457609.